July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Efficacy of Micropulse Laser Trabeculoplasty in Open Angle Glaucoma
Author Affiliations & Notes
  • antonella clemente
    Eye Unit, University Hospital Maggiore della Carità, Novara, Italy
  • Caterina Toma
    Eye Unit, University Hospital Maggiore della Carità, Novara, Italy
  • Stela Vujosevic
    Eye Unit, University Hospital Maggiore della Carità, Novara, Italy
  • chiara padovan
    science of healt, Universita del Piemonte Orientale, Italy
  • stefano de cillà
    Eye Unit, University Hospital Maggiore della Carità, Novara, Italy
    science of healt, Universita del Piemonte Orientale, Italy
  • Footnotes
    Commercial Relationships   antonella clemente, None; Caterina Toma, None; Stela Vujosevic, None; chiara padovan, None; stefano de cillà, None
  • Footnotes
    Support  No
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 696. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      antonella clemente, Caterina Toma, Stela Vujosevic, chiara padovan, stefano de cillà; Efficacy of Micropulse Laser Trabeculoplasty in Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2019;60(9):696.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of micropulse laser trabeculoplasty(MLT) in reducing intraocular pressure(IOP) and slowing down visual field(VF) defect progression in patients affected by poorly controlled OAG during a period of 6 months.

Methods : 45 eyes of 26 patients underwent a single MLT treatment using a Diode True-Yellow 577-nm Laser with MicroPulse technology (IQ 577 Laser System, Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA). Inclusion criteria: diagnosis of OAG; use of antiglaucoma drugs for at least 6 months without satisfactory IOP reduction and/or with VF defects progression. Exclusion criteria: angle closure glaucoma; previous glaucoma surgery/laser; concomitant ocular diseases requiring surgery; corneal anomalies. At baseline, each patient underwent a complete ophthalmologic examination with best-corrected visual acuity(BCVA) and IOP measurement, slit-lamp examination, gonioscopy and VF testing (SAP, Humphrey Visual Field Analyzer 24-2). After treatment, visits were scheduled at 1 week and 1, 3 and 6 months. BCVA and IOP measurement, slit-lamp examination and gonioscopy were performed at each visit, while VF testing was repeated only during the last visit. IOP and mean defect(MD) on VF testing were evaluated prior and after treatment in the entire population and in 4 subgroups divided on the base of number of antiglaucoma agents taken.

Results : Mean IOP was 21.2 ± 6.12 mmHg at baseline, 17.73 ± 5.98 mmHg 1 week after MLT, 17.62 ± 6.01, 17.91 ± 6.1 and 18.16 ± 6.68 mmHg 1, 3 and 6 months after MLT respectively. IOP reduction started early and was significant at each visit compared to pre-MLT values (p<0.0125). IOP reduction compared to baseline was -16.37% 1 week after MLT, -16.89%, -15.52% and -14.34% 1, 3 and 6 months after MLT respectively (p<0.0001). Mean MD was -4.93 ± 8.35 at baseline and -5.38 ± 8.43 6 months after treatment (p=0.09). We found a more evident decreasing trend in post-MLT IOP values in groups taking less antiglaucoma drugs, with no statistical significance.

Conclusions : 577-nm MLT is an effective, safe, painless, potentially repeatable and cheap procedure. Our results confirm that it is effective in lowering IOP and stopping glaucoma damage progression in a period of 6 months in patients with poorly controlled OAG. Further investigation is warranted to determine the relationship between MLT efficacy and the number of antiglaucoma drugs taken.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×